Case Study

Disease area strategy: patient expectations for 2030

Shaping the disease area strategy and early drug development to meet patient expectations in 2030

Global Scope

Budget: £20 – 30k

Disease area strategy: patient expectations for 2030 - Think Next
Disease area strategy: patient expectations for 2030 - Think Next
Disease area strategy: patient expectations for 2030 - Think Next

Key Deliverables

0
patient-centric trends
0
indications explored
0
implications for asset development

Client

A pharma company exploring new disease areas for early assets

Key Question

How might we shape our disease area strategy and early assets to meet patient expectations in 2030?

Our approach

In collaboration with the client’s insight partner, we extracted insights from primary qualitative research with medical experts and patient associations, to select, evidence and present the key trends shaping patient expectations in 2030.

We ran an innovation scan to showcase ‘early signals’ of these trends and help our client understand potential implications for their assets’ development strategy (e.g. diversity in clinical trials, novel endpoints, digital companions…)

Results

We helped our client to identify patient-friendly exploratory endpoints, as well as digital solutions that may impact future patient journey

Client Feedback

Related Case Studies

Innovation with connected drug device

Investigating the opportunity for a connected drug device with patients & caregivers – a winning case for change?

Digital Therapeutics Landscape and patient adoption

Building the case for change for Digital Therapeutics in a large pharmaceutical company

Digital strategy: the patient of the future

Anticipating patients’ expectations for digital health in 5 years to future-proof digital strategy